SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
bjd12467-sup-0001-FigS1.tifimage/tif2064KFig S1. Polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis of NLRP1 (previously NALP1) A/G (rs2670660) and C/T (rs6502867) polymorphisms. (a) PCR-RFLP analysis of NLRP1 A/G (rs2670660) promoter polymorphism on 2·5% agarose gel electrophoresis: lanes 4 and 12, homozygous (AA) genotypes; lanes 6–9, heterozygous (AG) genotypes; lanes 1–3, 5, 10 and 11, homozygous (GG) genotypes; lane M, 100-bp DNA ladder. (b) PCR-RFLP analysis of NLRP1 C/T (rs6502867) intron polymorphism on 2·5% agarose gel electrophoresis: lanes 1, 2, 4–6 and 8, homozygous (CC) genotypes; lanes 3 and 7, heterozygous (CT) genotypes; lane M, 50-bp DNA ladder.
bjd12467-sup-0002-FigS2.tifimage/tif3453KFig S2. Melt curve analysis of NLRP1 (previously NALP1) and GAPDH showing specific amplification.
bjd12467-sup-0003-FigS3.tifimage/tif3179KFig S3. TaqMan endpoint fluorescence analysis for NLRP1 (previously NALP1) A/T (rs12150220) using dual-colour hydrolysis probes (FAM and VIC) by LightCycler®480 Real-Time PCR protocol. The three genotypes identified as AA, AT and TT based on fluorescence with channel 465–510 (FAM for ‘T’ allele) and channel 536–580 (VIC for ‘A’ allele). A no-template control (NTC) was used with the SNP genotyping assay.
bjd12467-sup-0004-FigS4.tifimage/tif3083KFig S4. Fold expression of NLRP1 (previously NALP1) mRNA in patients with generalized vitiligo (GV). (a) Fold expression of NLRP1 mRNA in 31 patients with stable and 91 patients with active vitiligo. Patients with active vitiligo showed 5·3-fold higher expression compared with patients with stable vitiligo, as determined by the 2∆∆Cp method. (b) Fold expression of NLRP1 mRNA in 52 male and 70 female patients with vitiligo. Female patients showed a 6·0-fold higher expression compared with male patients, as determined by the 2∆∆Cp method.
bjd12467-sup-0005-TableS1-S2.docWord document37K

Table S1. Demographic characteristics of generalized vitiligo (GV) patients and unaffected controls.

Table S2. Primers and restriction enzymes used for NLRP1 gene A/G promoter (rs2670660) and T/C (rs6502867) intron SNPs genotyping and gene expression analyses.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.